መነሻ500124 • BOM
add
Dr Reddy's Laboratories Ltd
የቀዳሚ መዝጊያ
₹1,194.55
የቀን ክልል
₹1,194.00 - ₹1,222.85
የዓመት ክልል
₹1,074.35 - ₹1,420.20
የገበያው አጠቃላይ ዋጋ
1.01 ት INR
አማካይ መጠን
59.31 ሺ
የዋጋ/ገቢ ምጥጥን
18.98
የትርፍ ክፍያ
0.66%
ዋና ልውውጥ
NSE
የገበያ ዜና
.INX
0.35%
3.22%
ፋይናንስ
የገቢ መግለጫ
ገቢ
የተጣራ ገቢ
(INR) | ሴፕቴ 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
ገቢ | 80.16 ቢ | 16.51% |
የሥራ ወጪ | 29.72 ቢ | 24.54% |
የተጣራ ገቢ | 12.55 ቢ | -15.18% |
የተጣራ የትርፍ ክልል | 15.66 | -27.20% |
ገቢ በሼር | 15.83 | -11.13% |
EBITDA | 22.02 ቢ | 8.53% |
ውጤታማ የግብር ተመን | 30.01% | — |
ቀሪ ሒሳብ ሉሆች
አጠቃላይ ንብረቶች
አጠቃላይ ተጠያቂነቶች
(INR) | ሴፕቴ 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ | 63.07 ቢ | -7.15% |
አጠቃላይ ንብረቶች | 465.96 ቢ | 34.27% |
አጠቃላይ ተጠያቂነቶች | 156.67 ቢ | 66.79% |
አጠቃላይ እሴት | 309.28 ቢ | — |
የሼሮቹ ብዛት | 833.05 ሚ | — |
የገበያ ዋጋ እና የተገለጸ ዋጋ | 3.26 | — |
የእሴቶች ተመላሽ | 10.24% | — |
የካፒታል ተመላሽ | 13.21% | — |
የገንዘብ ፍሰት
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ
(INR) | ሴፕቴ 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
የተጣራ ገቢ | 12.55 ቢ | -15.18% |
ከክወናዎች የተገኘ ጥሬ ገንዘብ | 9.32 ቢ | -48.03% |
ገንዘብ ከኢንቨስትመንት | -19.07 ቢ | -322.21% |
ገንዘብ ከፋይናንስ | 16.15 ቢ | 329.53% |
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ | 6.37 ቢ | 1.03% |
ነፃ የገንዘብ ፍሰት | 3.92 ቢ | -72.47% |
ስለ
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
ዋና ሥራ አስፈጻሚ
የተመሰረተው
1984
ዋና መሥሪያ ቤት
ድህረገፅ
ሠራተኞች
27,048